| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00401-009-0614-0 |
| P8608 | Fatcat ID | release_lggtq3dsuvgl7m6flxlax6o2mi |
| P932 | PMC publication ID | 2808538 |
| P698 | PubMed publication ID | 19936768 |
| P5875 | ResearchGate publication ID | 40030032 |
| P50 | author | Rob Hooft van Huijsduijnen | Q38601147 |
| Wiljan Hendriks | Q40334879 | ||
| Anna C Navis | Q42319322 | ||
| P2093 | author name string | Jan T G Schepens | |
| Pieter Wesseling | |||
| Monique van den Eijnden | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| The lipid phosphatase activity of PTEN is critical for its tumor supressor function | Q22007981 | ||
| Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta | Q22253290 | ||
| Site-selective dephosphorylation of the platelet-derived growth factor beta-receptor by the receptor-like protein-tyrosine phosphatase DEP-1 | Q22254150 | ||
| Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines | Q24290329 | ||
| Identification of STAT3 as a substrate of receptor protein tyrosine phosphatase T | Q24300141 | ||
| FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface | Q24300920 | ||
| Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions | Q24313501 | ||
| Dephosphorylation of the C-terminal tyrosyl residue of the DNA damage-related histone H2A.X is mediated by the protein phosphatase eyes absent | Q24313879 | ||
| The cloning of a receptor-type protein tyrosine phosphatase expressed in the central nervous system | Q24315114 | ||
| Tumor-derived extracellular mutations of PTPRT /PTPrho are defective in cell adhesion | Q24316023 | ||
| The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate | Q24317714 | ||
| Protein tyrosine phosphatases: structure-function relationships | Q37094073 | ||
| Angiogenesis and gliomas: current issues and development of surrogate markers | Q37094967 | ||
| Metalloproteinase- and gamma-secretase-mediated cleavage of protein-tyrosine phosphatase receptor type Z | Q37142719 | ||
| Development of a novel mouse glioma model using lentiviral vectors | Q37164106 | ||
| PTEN signaling in brain: neuropathology and tumorigenesis. | Q37270423 | ||
| The role of PTEN signaling perturbations in cancer and in targeted therapy | Q37270446 | ||
| PTEN signaling pathways in glioblastoma | Q37287036 | ||
| Designer therapies for glioblastoma multiforme | Q37319650 | ||
| Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer. | Q37340004 | ||
| Genetically engineered mouse models of brain cancer and the promise of preclinical testing | Q37348716 | ||
| Function of mitochondrial Stat3 in cellular respiration | Q37378567 | ||
| Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma | Q37385138 | ||
| Sensing invasion: cell surface receptors driving spreading of glioblastoma. | Q37581541 | ||
| A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. | Q38444234 | ||
| Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. | Q39675800 | ||
| Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway | Q39802740 | ||
| Rosiglitazone reduces cell invasiveness by inducing MKP-1 in human U87MG glioma cells | Q39891033 | ||
| Dexamethasone reduced invasiveness of human malignant glioblastoma cells through a MAPK phosphatase-1 (MKP-1) dependent mechanism | Q39957672 | ||
| Cadmium specifically induces MKP-1 expression via the glutathione depletion-mediated p38 MAPK activation in C6 glioma cells | Q39969065 | ||
| Phenotypic and genotypic characterization of orthotopic human glioma models and its relevance for the study of anti-glioma therapy. | Q39997794 | ||
| Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G(2)/M arrest in glioblastoma cell lines. | Q40127963 | ||
| A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity | Q40241085 | ||
| RNA interference targeting protein tyrosine phosphatase zeta/receptor-type protein tyrosine phosphatase beta suppresses glioblastoma growth in vitro and in vivo | Q40241308 | ||
| High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma | Q40296399 | ||
| Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model | Q40314272 | ||
| Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines | Q40352167 | ||
| FAS associated phosphatase (FAP-1) blocks apoptosis of astrocytomas through dephosphorylation of FAS. | Q40368462 | ||
| Functional comparison of long and short splice forms of RPTPbeta: implications for glioblastoma treatment | Q40435239 | ||
| PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis | Q40443869 | ||
| The phosphotyrosine phosphatase eta mediates somatostatin inhibition of glioma proliferation via the dephosphorylation of ERK1/2. | Q40468850 | ||
| Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas | Q40604566 | ||
| Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR | Q40619097 | ||
| Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells | Q40685493 | ||
| Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. | Q40707507 | ||
| The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors | Q40775807 | ||
| The protein tyrosine phosphatase TCPTP suppresses the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth factor receptor. | Q40784926 | ||
| Protein tyrosine phosphatases take off. | Q41143264 | ||
| The protein tyrosine phosphatase DEP-1 is induced during differentiation and inhibits growth of breast cancer cells. | Q41167843 | ||
| Cell-cycle arrest and p53 accumulation induced by geldanamycin in human ovarian tumour cells | Q41254067 | ||
| Mechanisms of glioma invasion: role of matrix-metalloproteinases | Q41357018 | ||
| Structural, catalytic, and functional properties of low M(r), phosphotyrosine protein phosphatases. Evidence of a long evolutionary history. | Q41467925 | ||
| Histological characteristics and expression of acidic and basic fibroblast growth factor genes in intracerebral xenogeneic transplants of human glioma cells | Q41507245 | ||
| In vitro and in vivo models for the study of brain tumour invasion | Q41680942 | ||
| Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. | Q41710409 | ||
| Protein phosphatase Dusp26 associates with KIF3 motor and promotes N-cadherin-mediated cell-cell adhesion | Q24319686 | ||
| Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2 | Q24319816 | ||
| P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase | Q24322705 | ||
| Hepatocyte growth factor receptor tyrosine kinase met is a substrate of the receptor protein-tyrosine phosphatase DEP-1 | Q24329131 | ||
| KAP: a dual specificity phosphatase that interacts with cyclin-dependent kinases | Q24336439 | ||
| A human transmembrane protein-tyrosine-phosphatase, PTP zeta, is expressed in brain and has an N-terminal receptor domain homologous to carbonic anhydrases | Q24337062 | ||
| Cloning and characterization of a mouse cDNA encoding a cytoplasmic protein-tyrosine-phosphatase | Q24563410 | ||
| cDNA isolated from a human T-cell library encodes a member of the protein-tyrosine-phosphatase family | Q24611364 | ||
| The role of protein tyrosine phosphatase 1B in Ras signaling | Q24622106 | ||
| Somatic mutations affect key pathways in lung adenocarcinoma | Q24648102 | ||
| PTPmu suppresses glioma cell migration and dispersal | Q24650475 | ||
| Proteolytic cleavage of protein tyrosine phosphatase mu regulates glioblastoma cell migration | Q24650562 | ||
| Comprehensive genomic characterization defines human glioblastoma genes and core pathways | Q24656128 | ||
| The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 | ||
| Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma | Q24670606 | ||
| The 2007 WHO classification of tumours of the central nervous system | Q24685772 | ||
| Structure of a tyrosine phosphatase adhesive interaction reveals a spacer-clamp mechanism | Q27647696 | ||
| Surfing the p53 network | Q28032484 | ||
| The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers | Q28115840 | ||
| A phosphatase associated with metastasis of colorectal cancer | Q28198115 | ||
| PTEN: one gene, many syndromes | Q28203387 | ||
| Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers | Q28207853 | ||
| A role for receptor tyrosine phosphatase zeta in glioma cell migration | Q28209273 | ||
| The expression of the phosphotyrosine phosphatase DEP-1/PTPeta dictates the responsivity of glioma cells to somatostatin inhibition of cell proliferation | Q28259893 | ||
| Protein tyrosine phosphatases in the human genome | Q28265924 | ||
| Multi-ligand interactions with receptor-like protein tyrosine phosphatase beta: implications for intercellular signaling | Q28270605 | ||
| Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers | Q28306997 | ||
| Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma | Q28472048 | ||
| A mutant receptor tyrosine phosphatase, CD148, causes defects in vascular development | Q28508534 | ||
| 6B4 proteoglycan/phosphacan, an extracellular variant of receptor-like protein-tyrosine phosphatase zeta/RPTPbeta, binds pleiotrophin/heparin-binding growth-associated molecule (HB-GAM) | Q28565680 | ||
| Protein tyrosine phosphatase receptor type Z is inactivated by ligand-induced oligomerization | Q28572036 | ||
| Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial | Q29547224 | ||
| Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors | Q42493757 | ||
| Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. | Q42807109 | ||
| A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells | Q44236067 | ||
| Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia | Q44419404 | ||
| The putative serine/threonine kinase gene STK15 on chromosome 20q13.2 is amplified in human gliomas | Q44527697 | ||
| Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis | Q44673842 | ||
| Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. | Q44760563 | ||
| Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo | Q45134010 | ||
| Integrin alpha(v)beta(3) is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase beta/zeta. | Q45904605 | ||
| Protein tyrosine phosphatase receptor type Z dephosphorylates TrkA receptors and attenuates NGF-dependent neurite outgrowth of PC12 cells | Q46597824 | ||
| The value and correlation between PRL-3 expression and matrix metalloproteinase activity and expression in human gliomas | Q46894619 | ||
| A silver lining on the horizon for glioblastoma | Q47896945 | ||
| Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo | Q48088819 | ||
| Aberrant splicing of cyclin-dependent kinase-associated protein phosphatase KAP increases proliferation and migration in glioblastoma | Q48315949 | ||
| Relationship between the expression of E-, N-cadherins and beta-catenin and tumor grade in astrocytomas | Q48543014 | ||
| Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer. | Q53335960 | ||
| Genetic ablation of Ptprj, a mouse cancer susceptibility gene, results in normal growth and development and does not predispose to spontaneous tumorigenesis. | Q53616336 | ||
| The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. | Q55467692 | ||
| Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma. | Q55467851 | ||
| The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. | Q55472363 | ||
| PTEN mutation and epidermal growth factor receptor activation regulate vascular endothelial growth factor (VEGF) mRNA expression in human glioblastoma cells by transactivating the proximal VEGF promoter. | Q55473076 | ||
| Activation of transcription via AP-1 or CREB regulatory sites is blocked by protein tyrosine phosphatases | Q68247110 | ||
| Three forms of RPTP-beta are differentially expressed during gliogenesis in the developing rat brain and during glial cell differentiation in culture | Q71302841 | ||
| Geldanamycin induces cell cycle arrest in K562 erythroleukemic cells | Q73347967 | ||
| Relationship between serum concentrations of the growth factor pleiotrophin and pleiotrophin-positive tumors | Q77425401 | ||
| Cdc25 phosphatases: structure, specificity, and mechanism | Q36747424 | ||
| The eyes absent family of phosphotyrosine phosphatases: properties and roles in developmental regulation of transcription | Q36752910 | ||
| PTP1B as a drug target: recent developments in PTP1B inhibitor discovery | Q36805716 | ||
| Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma | Q36825199 | ||
| Molecularly targeted therapy for malignant glioma | Q36829847 | ||
| CDC25 phosphatases in cancer cells: key players? Good targets? | Q36849329 | ||
| Diffuse glioma growth: a guerilla war | Q36931690 | ||
| Protein tyrosine phosphatases: emerging regulators of apoptosis | Q36999614 | ||
| Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker. | Q37010985 | ||
| PI3K signaling in glioma--animal models and therapeutic challenges | Q37039348 | ||
| PTPL1: a large phosphatase with a split personality | Q37081432 | ||
| The tyrosine phosphatase Shp2 (PTPN11) in cancer. | Q37088972 | ||
| Protein tyrosine phosphatases: functional inferences from mouse models and human diseases. | Q37094061 | ||
| Protein tyrosine phosphatases: dual-specificity phosphatases in health and disease | Q37094068 | ||
| The TOR pathway: a target for cancer therapy | Q29614242 | ||
| The STATs of cancer--new molecular targets come of age | Q29614601 | ||
| Protein tyrosine phosphatases: from genes, to function, to disease | Q29614826 | ||
| Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines | Q29615823 | ||
| Malignant astrocytic glioma: genetics, biology, and paths to treatment | Q29618156 | ||
| Telomerase and the maintenance of chromosome ends | Q30304123 | ||
| Interactions between PTEN and receptor tyrosine kinase pathways and their implications for glioma therapy | Q30437740 | ||
| Mouse models of brain tumors and their applications in preclinical trials | Q31062292 | ||
| A survey of homozygous deletions in human cancer genomes | Q33934322 | ||
| The T-cell protein tyrosine phosphatase | Q34038105 | ||
| Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B. | Q34158339 | ||
| Mutational analysis of the tyrosine phosphatome in colorectal cancers | Q34322220 | ||
| Identification of chromosome arm 9p as the most frequent target of homozygous deletions in lung cancer | Q34444611 | ||
| Genetic ablation of protein tyrosine phosphatase 1B accelerates lymphomagenesis of p53-null mice through the regulation of B-cell development | Q34464803 | ||
| Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis | Q34607187 | ||
| Angiocentric glioma: report of clinico-pathologic and genetic findings in 8 cases | Q34655465 | ||
| Genomic changes in progression of low-grade gliomas | Q34794665 | ||
| Drug delivery to the central nervous system: a review | Q35205301 | ||
| A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity | Q35660849 | ||
| Genetic pathways to primary and secondary glioblastoma | Q35757144 | ||
| Prognostic significance of CDC25B expression in gliomas | Q35770127 | ||
| HIF1 and oxygen sensing in the brain | Q35777630 | ||
| Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis | Q35800467 | ||
| Pleiotrophin transforms NIH 3T3 cells and induces tumors in nude mice | Q36067348 | ||
| Impaired learning with enhanced hippocampal long-term potentiation in PTPdelta-deficient mice | Q36080560 | ||
| Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis | Q36084509 | ||
| Involvement of the small protein tyrosine phosphatases TC-PTP and PTP1B in signal transduction and diseases: from diabetes, obesity to cell cycle, and cancer | Q36274061 | ||
| Glioma: what is the role of c-Myc, hsp90 and telomerase? | Q36380915 | ||
| Protein-tyrosine phosphatases and cancer | Q36430193 | ||
| The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth | Q36483794 | ||
| RB and cell cycle progression | Q36579245 | ||
| Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction | Q36599297 | ||
| Vascular endothelial growth factor expression is independent of hypoxia in human malignant glioma spheroids and tumours | Q36621192 | ||
| Receptor protein tyrosine phosphatase from stem cells to mature glial cells of the central nervous system | Q36645426 | ||
| Phosphorylation of protein kinase Cdelta on distinct tyrosine residues induces sustained activation of Erk1/2 via down-regulation of MKP-1: role in the apoptotic effect of etoposide | Q36719264 | ||
| P433 | issue | 2 | |
| P921 | main subject | brain tumor | Q233309 |
| protein tyrosine phosphatase | Q643602 | ||
| signal transduction | Q828130 | ||
| glioma | Q1365309 | ||
| P304 | page(s) | 157-175 | |
| P577 | publication date | 2009-11-21 | |
| 2010-02-01 | |||
| P1433 | published in | Acta Neuropathologica | Q343168 |
| P1476 | title | Protein tyrosine phosphatases in glioma biology | |
| P478 | volume | 119 |
| Q34292538 | Antitumor activity of (R,R')-4-methoxy-1-naphthylfenoterol in a rat C6 glioma xenograft model in the mouse |
| Q53214911 | Cerebrospinal fluid stimulates leptomeningeal and meningioma cell proliferation and activation of STAT3. |
| Q38438854 | Comprehensive protein tyrosine phosphatase mRNA profiling identifies new regulators in the progression of glioma |
| Q35767449 | CpG array analysis of histone H3 lysine 4 trimethylation by chromatin immunoprecipitation linked to microarrays analysis in peripheral blood mononuclear cells of IgA nephropathy patients |
| Q39546149 | Cytotoxic effect of menadione and sodium orthovanadate in combination on human glioma cells |
| Q33952447 | DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma. |
| Q48472764 | Deletion of Atf6α impairs astroglial activation and enhances neuronal death following brain ischemia in mice |
| Q39458568 | Dynamin 2 mediates PDGFRα-SHP-2-promoted glioblastoma growth and invasion |
| Q52345443 | Exploring the pathogenesis of canine epilepsy using a systems genetics method and implications for anti-epilepsy drug discovery. |
| Q51013033 | IGF2 mRNA binding protein 3 (IMP3) mediated regulation of transcriptome and translatome in glioma cells. |
| Q34483732 | Intracellular and extracellular domains of protein tyrosine phosphatase PTPRZ-B differentially regulate glioma cell growth and motility |
| Q33858514 | Metabolic regulation by protein tyrosine phosphatases |
| Q64053704 | Multicellular gene network analysis identifies a macrophage-related gene signature predictive of therapeutic response and prognosis of gliomas |
| Q52647666 | PRL-3 is a potential glioblastoma prognostic marker and promotes glioblastoma progression by enhancing MMP7 through the ERK and JNK pathways. |
| Q39117557 | Preclinical evaluation of dipotassium bisperoxo (picolinato) oxovanadate V for the treatment of pediatric low-grade gliomas |
| Q64245074 | Protein Phosphatases-A Touchy Enemy in the Battle Against Glioblastomas: A Review |
| Q35914525 | Protein tyrosine phosphatase mu regulates glioblastoma cell growth and survival in vivo |
| Q48753389 | Protein tyrosine phosphatase receptor U (PTPRU) is required for glioma growth and motility |
| Q38039493 | Protein tyrosine phosphatases in health and disease |
| Q50033709 | Proteinaceous Regulators and Inhibitors of Protein Tyrosine Phosphatases. |
| Q53170708 | Radiation effects on human leptomeningeal cell response to cerebrospinal fluid and PDGF-BB. |
| Q98771197 | SHP-2-Mediated Upregulation of ZEB1 Is Important for PDGF-B-Induced Cell Proliferation and Metastatic Phenotype in Triple Negative Breast Cancer |
| Q41917289 | SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans |
| Q39665434 | Shp2 Deficiency Impairs the Inflammatory Response Against Haemophilus influenzae by Regulating Macrophage Polarization |
| Q36393427 | Shp2 plays an important role in acute cigarette smoke-mediated lung inflammation |
| Q38096247 | Signaling mechanisms regulating myelination in the central nervous system. |
| Q35917698 | Small-molecule inhibition of PTPRZ reduces tumor growth in a rat model of glioblastoma |
| Q39167357 | Src homology 2-containing protein tyrosine phosphatase-2 acts as a negative regulator for MUC5AC transcription via the inhibition of the ERK1/2 MAPK signalling pathway in the airway |
| Q33912275 | Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells. |
| Q47317704 | The protein tyrosine phosphatase Shp2 regulates oligodendrocyte differentiation and early myelination and contributes to timely remyelination. |
| Q35747480 | Tissue-specific alterations of PRL-1 and PRL-2 expression in cancer |
| Q33928558 | Tyrosine phosphatase Shp2 mediates the estrogen biological action in breast cancer via interaction with the estrogen extranuclear receptor |
Search more.